Source - SMW
OptiBiotix Health has entered into a three-year supply agreement with HLH BioPharma Vertriebs GmbH covering the supply of LPLDL capsules. 

The agreement granted HLH a non-exclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LPLDL strain with a view to maximising the financial return for both parties. 

This agreement followed on from the sales order of 100,000 units of LPLDL to HLH announced on 25 April 2017 and reflected growing consumer interest and distributor confidence in the products market appeal.